PHARMACIA AND UPJOHN
TO MERGE

From The Cancer Chronicles #29
© 1995 by Ralph W. Moss, Ph.D.

The march towards monopoly in the drug field continues unabated. On August 20, the US giant Upjohn and the Swedish company Pharmacia announced plans to merge. The goal of the new company, called Pharmacia & Upjohn, will not just share product lines and sales forces but to cut costs. First thing, it will lay off 4,000 workers.

The new company will be among the world¹s ten largest drug firms, with around $7 billion in annual sales. The announcement came two days after Rhone-Poulenc Rorer launched a hostile bid for the British Fisons company. The Swedish government owns 14 percent of Pharmacia. One of the focuses of the new company will be anticancer drugs. "For its part, the Scandinavian group brings new products to the party--particularly in cancer care" said the Financial Times (8/21/95).

Some party!

Pharmacia has recently expressed interest in developing innovative immunological products for cancer. One can only hope. In the meantime, patients and alternative practitioners confront an ever-narrowing circle of ever-more-powerful allopathic drug producers.


articles on
economics of cancer



Ralph W. Moss, Ph.D. is director of the The Moss Reports for cancer patients. Dr. Moss is the author of eleven books and three documentaries on cancer-related topics. He is or has been an advisor on alternative cancer treatments to the National Institutes of Health, the National Cancer Institute, the American Urological Association, Columbia University, the University of Texas, the Susan G. Komen Foundation and the German Society of Oncology. He wrote the first article on alternative medicine for the Encyclopedia Britannica yearbook. He is listed in Marquis Who's Who in America, Who's Who in the World, Who's Who in the East, and Who's Who in Entertainment (as a film documentarian). This Web site does not advocate any particular treatment for cancer. We urge you to always seek competent medical advice for all health problems, especially cancer. Before consulting our site please read our full Disclaimer statement.



home - moss reports - books - - contact - order - news
members - chronicles - faq - free email newsletter